Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34132735/
Of patients with ASCVD, most with suboptimal LDL-C levels at baseline, only 17.1% had LLT intensification after 2 years, and two-thirds remained at an LDL-C level greater than 70 mg/dL....
-
Dr Hamid4yrGuidelines for patients with atherosclerotic cardiovascular disease (ASCVD) recommend intensive statin therapy and adding nonstatin therapy if low-density lipoprotein cholesterol (LDL-C) levels are 70 mg/dL or more. Compliance with guidelines Show More
-
Lipid Management Connect4yrHi there! That's a great question. Pharmaceutical manufacturers occasionally sponsor content within our communities. This allows us to provide membership free of charge, and our privacy policy safeguards your personally Show More
Elevated Apolipoprotein A1 and HDL Cholesterol Associated with Age-related Macular Degeneration: 2 Population Cohorts - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33596319/
1 Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen,Denmark. 2 The Copenhagen General Population Study, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev,Denmark. 3 Department of Clinical Medicine, Faculty...
MiR-145-5p modulates lipid metabolism and M2 macrophage polarization by targeting PAK7 and regulating β-catenin signaling in hyperlipidemia
Source : https://cdnsciencepub.com/doi/abs/10.1139/cjpp-2020-0539
Canadian Journal of Physiology and Pharmacology The present study aims to explore the role of microRNA 145-5p (miR-145-5p) in hyperlipidemia. Using bioinformatics tools and a wide range of function and...
Pharmacokinetics and pharmacodynamics of HTD1801 (berberine ursodeoxycholate, BUDCA) in patients with hyperlipidemia
Source : https://lipidworld.biomedcentral.com/articles/10.1186/s12944-020-01406-4
Background Reduction in elevated serum cholesterol concentrations is important in the management of individuals at risk of atherosclerotic cardiovascular disease (ASCVD), such as myocardial infarction and thrombotic stroke. Although HMGCoA...
